CureVac NV (Germany) Top Insiders
| 5CV Stock | EUR 3.45 0.03 0.86% |
CureVac NV employs about 764 people. The company is managed by 10 executives with a total tenure of roughly 1783 years, averaging almost 178.0 years of service per executive, having 76.4 employees per reported executive. Examination of CureVac NV's management performance can provide insight into the company performance.
| Pierre BSc Insider CFO MD |
| Ulrike MD Insider Sr Officer |
CureVac |
CureVac NV Management Team Effectiveness
The company has return on total asset (ROA) of (0.3424) % which means that it has lost $0.3424 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1851) %, meaning that it generated substantial loss on money invested by shareholders. CureVac NV's management efficiency ratios could be used to measure how well CureVac NV manages its routine affairs as well as how well it operates its assets and liabilities.CureVac NV Workforce Comparison
CureVac NV is number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is presently estimated at about 9,638. CureVac NV holds roughly 764 in number of employees claiming about 8% of stocks in Biotechnology industry.
The company has Profit Margin (PM) of (1.26) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (7.27) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $7.27. CureVac NV Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. CureVac NV Price Series Summation is a cross summation of CureVac NV price series and its benchmark/peer.
CureVac NV Notable Stakeholders
A CureVac NV stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as CureVac NV often face trade-offs trying to please all of them. CureVac NV's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting CureVac NV's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Pierre BSc | CFO MD | Profile | |
| Ulrike MD | Sr Officer | Profile | |
| Slavica StevanovicHeck | Head HR | Profile | |
| Thorsten Schuller | Head Communications | Profile | |
| Igor MSc | Chief Board | Profile | |
| Antony Blanc | Chief MD | Profile | |
| Malte Greune | Member COO | Profile | |
| Sarah Fakih | VP Relations | Profile | |
| LLM LLM | Member CEO | Profile | |
| Marco LLM | G Counsel | Profile |
About CureVac NV Management Performance
The success or failure of an entity such as CureVac NV often depends on how effective the management is. CureVac NV management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CureVac management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CureVac management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid . The company was founded in 2000 and is headquartered in Tbingen, Germany. CUREVAC N operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 455 people.
CureVac NV Workforce Analysis
Traditionally, organizations such as CureVac NV use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare CureVac NV within its industry.CureVac NV Manpower Efficiency
Return on CureVac NV Manpower
| Revenue Per Employee | 134.8K | |
| Revenue Per Executive | 10.3M | |
| Net Loss Per Employee | 538.9K | |
| Net Loss Per Executive | 41.2M |
Complementary Tools for CureVac Stock analysis
When running CureVac NV's price analysis, check to measure CureVac NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CureVac NV is operating at the current time. Most of CureVac NV's value examination focuses on studying past and present price action to predict the probability of CureVac NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CureVac NV's price. Additionally, you may evaluate how the addition of CureVac NV to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |